Completed PHASE1/PHASE2 INTERVENTIONAL 5-arm NCT00602030

Study to Evaluate Erlotinib With or Without SNDX-275 (Entinostat) in the Treatment of Patients With Advanced NSCLC

A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 2 Study With a Lead in Phase of Erlotinib With or Without SNDX-275 in Patients With NSCLC After Failure In Up to Two Prior Chemotherapeutic Regimens for Advanced Disease

Sponsor: Syndax Pharmaceuticals

Conditions Carcinoma, Non-Small Cell Lung Non-Small-Cell Lung Carcinoma

Interventions Entinostat Erlotinib Placebo

Updated 9 times since 2017 Last updated: Aug 18, 2022 Started: Jan 8, 2008 Primary completion: Feb 4, 2010 Completion: Feb 1, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00602030, this PHASE1/PHASE2 trial focuses on Carcinoma, Non-Small Cell Lung and Non-Small-Cell Lung Carcinoma and remains completed. Sponsored by Syndax Pharmaceuticals, it has been updated 9 times since 2008, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

9 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE1/PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Sep 2022 — Jul 2024 [monthly]

Completed PHASE1_PHASE2
Jul 2022 — Sep 2022 [monthly]

Completed PHASE1_PHASE2

▶ Show 4 earlier versions

Jan 2021 — Jul 2022 [monthly]

Completed PHASE1_PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1_PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE1_PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE1_PHASE2

First recorded

Jan 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Syndax Pharmaceuticals

Data source: Syndax Pharmaceuticals

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Amarillo, United States , Austin, United States , Bedford, United States , Boardman, United States , Burien, United States , Chicago, United States , Dallas, United States , Denver, United States , Eugene, United States , Fairfax, United States and 19 more locations